Auranofin Attenuates Non-Alcoholic Fatty Liver Disease by Suppressing Lipid Accumulation and NLRP3 Inflammasome-Mediated Hepatic Inflammation In Vivo and In Vitro

• Autors principals: Hyun Hwangbo (Autor), Min Yeong Kim (Autor), Seon Yeong Ji (Autor), So Young Kim (Autor), Hyesook Lee (Autor), Gi-Young Kim (Autor), Cheol Park (Autor), Young-Sam Keum (Autor), Su Hyun Hong (Autor), Jaehun Cheong (Autor), Yung Hyun Choi (Autor)
• Format: Llibre
• Publicat: MDPI AG, 2020-10-01T00:00:00Z.
• Matèries: article
• Accés en línia: Connect to this object online.

Non-alcoholic fatty liver disease (NAFLD) causes liver dysfunction and is associated with obesity and type 2 diabetes. Chronic inflammation is associated not only with the development of NAFLD, but also with hepatic diseases, including steatohepatitis, cirrhosis, and hepatocellular carcinoma. Aurano...